2. Gene
  3. CRBN - cereblon Gene

CRBN - cereblon Gene

  • 基因
  • 蛋白
  • 疾病
  • 相关产品
  • 直系同源

中文名称：大脑

种属: Homo sapiens

同用名: MRT2; MRT2A

基因 ID: 51185 | 基因类型: protein coding

关于 CRBN

Cytogenetic location: 3p26.2 Genomic coordinates (GRCh38): 3:3,149,633-3,179,717 (from NCBI)

This gene has 14 transcripts (splice variants), 207 orthologues and is associated with 3 phenotypes. Ubiquitous expression in testis (RPKM 17.6), brain (RPKM 16.5) and 25 other tissues.

功能概要

该基因编码与 Lon 蛋白酶蛋白家族相关的蛋白质。在啮齿类动物和其他哺乳动物中，这种基因产物存在于细胞质中，钙通道膜蛋白定位于此，并被认为在大脑发育中发挥作用。该基因的突变与常染色体隐性非综合征性认知障碍有关。已发现该基因编码不同异构体的多个转录变体。[RefSeq 提供，2010 年 3 月]

This gene encodes a protein related to the Lon Protease protein family. In rodents and other mammals this gene product is found in the cytoplasm localized with a Calcium Channel membrane protein, and is thought to play a role in brain development. Mutations in this gene are associated with autosomal recessive nonsyndromic cognitive disability. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2010]

CRBN 基因产物(4)

mRNA Protein Name
NM_001173482.1 NP_001166953.1 protein cereblon isoform 2
NM_016302.4 NP_057386.2 protein cereblon isoform 1
NM_001173482.1 NP_001166953.1 protein cereblon isoform 2
NM_016302.4 NP_057386.2 protein cereblon isoform 1
基因本体论
  • 分子功能
  • 生物过程
  • 细胞组分
分子功能 GO 注释 逻辑证据 参考文献 来源
enables protein binding IPI
IPI: 通过物理相互作用推断
20223979 GOA
生物过程 GO 注释 逻辑证据 参考文献 来源
involved in positive regulation of Wnt signaling pathway IMP
IMP: 通过突变表型推断
34489457 GOA
involved in proteasome-mediated ubiquitin-dependent protein catabolic process IMP
IMP: 通过突变表型推断
20223979 GOA
involved in protein ubiquitination IMP
IMP: 通过突变表型推断
20223979 GOA
细胞组分 GO 注释 逻辑证据 参考文献 来源
part of Cul4A-RING E3 ubiquitin ligase complex IDA
IDA: 通过直接分析推断
20223979 GOA
located in cytoplasm IDA
IDA: 通过直接分析推断
20223979 GOA
located in nucleus IDA
IDA: 通过直接分析推断
20223979 GOA
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

CRBN 蛋白结构

LON_substr_bdg

LON_substr_bdg: ATP-dependent protease La (LON) substrate-binding domain (80 - 317)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 442 a.a.
蛋白主名 其他名称

protein cereblon

protein x 0001

关联疾病

疾病名称 别名
Intellectual Developmental Disorder, Autosomal Recessive 2

Mental Retardation, Autosomal Recessive 2a

MRT2

Mental Retardation, Autosomal Recessive 2

Mrt2a

Autosomal Recessive Intellectual Developmental Disorder 2

Mental Retardation, Autosomal Recessive, Type 2
Autosomal Recessive Non-Syndromic Intellectual Disability

Ar-Nsid

Ns-Arid
Plasma Cell Neoplasm

Plasma Cell Dyscrasia

Paraproteinemias

Plasma Cell Tumour

Plasmacytic Tumor

Multiple Myeloma

Plasmacytoma

Plasma Cell Tumours

Plasma Cells Dyscrasia
Myeloma, Multiple

Multiple Myeloma

Plasma Cell Myeloma

Kahler Disease

Myelomatosis

Medullary Plasmacytoma

Multiple Myeloma, Resistance To

Myeloma

Plasma Cell Dyscrasia

Kahler'S Disease

Multiple Myeloma, Susceptibility To

Myeloma - Multiple

Kahler-Bozzolo Disease

Plasma Cell Myelomas

MM

Plasma Cell Neoplasm

Primary Systemic Amyloidosis

Primary Amyloidosis

Immunoglobulin Deposition Disease

Plasmacytic Myeloma

Multiple Myelomata

Multiple Myeloma Nos

Multiple Myeloma Without Mention Of Remission

Monostotic Plasma Cell Myeloma

Mm - [Multiple Myeloma]
Erythema Nodosum
Duane-Radial Ray Syndrome

Okihiro Syndrome

DRRS

Dr Syndrome

Duane Anomaly With Radial Ray Abnormalities And Deafness

Acrorenoocular Syndrome

Acrorenocular Syndrome

Duane Anomaly With Radial Abnormalities And Deafness

Acro-Renal-Ocular Syndrome
Chromosome 3pter-P25 Deletion Syndrome

3p- Syndrome

3p Deletion Syndrome

Distal Monosomy 3p

Chromosome 3, Monosomy 3p

3p Partial Monosomy Syndrome

Chromosome 3, Deletion 3p

Chromosome 3p Deletion Syndrome

Del Syndrome

Deletion 3p

Monosomy 3p

Partial Monosomy 3p

Distal 3p Deletion

Monosomy 3pter

Telomeric Monosomy 3p

Chromosome Deletion Syndrome 3pter-P25
Autosomal Recessive Intellectual Developmental Disorder

Mental Retardation, Autosomal Recessive

Autosomal Recessive Mental Retardation

Autosomal Recessive Non-Syndromic Mental Retardation

Autosomal Recessive Non-Syndromic Intellectual Disability
Non-Secretory Myeloma
Smoldering Myeloma
Bone Marrow Cancer

Malignant Neoplasm Of Bone Marrow

Bone Marrow Neoplasm

Bone Marrow Tumor

Malignant Bone Marrow Tumor

Myeloproliferative Disorders

Bone Marrow Neoplasms

Myeloproliferative Disease

Chronic Myeloproliferative Disorder
Monoclonal Gammopathy Of Uncertain Significance

Monoclonal Gammopathy Of Undetermined Significance

Mgus

Mgus - [Monoclonal Gammopathy Of Undetermined Significance]

Monoclonal Gammopathy Nos

Iga Gammopathy

Monoclonal Gammoglobulinopathy
Thrombocytopenia

Low Platelet Count

Low Platelets

Decreased Platelets

Platelet Dysfunction Nos
Leukocyte Disease

Leukocyte Disorders
Leprosy 3

Leprosy

Leprosy, Susceptibility To, 3

Hansen'S Disease

Leprosy, Susceptibility To

Hansen Disease

Infection Due To Mycobacterium Leprae

LPRS3

Leprosy, Type 3

Anaesthesia Leprosy

Anaesthetic Leprosy

Maculoanaesthetic Leprosy

Macular Leprosy

Leprosy Unspecified
Mantle Cell Lymphoma

Lymphoma, Mantle Cell

Lcm

Mcl

Mantle Zone Lymphoma

Lymphoma Mantle-Cell

Lymphoma, Mantle-Cell

Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse

Malignant Lymphoma - Lymphocytic, Intermediate Differentiation

Diffuse Small Cleaved-Cell Lymphoma

Diffuse Small Cleaved Cell Malignant Lymphoma

Small Cleaved Cell Non-Hodgkin Lymphoma

Diffuse Non-Hodgkin Small Cleaved Cell Lymphoma

Malignant Lymphomatous Polyposis

Malignant Small Cell, Noncleaved, Diffuse Lymphoma

Malignant Undifferentiated Cell, Non-Burkitt Lymphoma

Cleaved Cell Lymphoma

Small Cell Mantle Cell Lymphoma

Small Cleaved Cell Malignant Lymphoma
Myelodysplastic Syndrome

Myelodysplastic Syndromes

Myelodysplasia

MDS

Myelodysplastic Syndrome Included

Myelodysplastic Syndrome, Susceptibility To, Included

Myelodysplastic Syndrome, Somatic

Myelodysplastic Syndrome, Susceptibility To
Leukemia, Acute Myeloid

Acute Myeloid Leukemia

Leukemia, Acute Myelogenous

Acute Myelogenous Leukemia

AML

Leukemia, Acute Myeloid, Susceptibility To

Acute Myeloblastic Leukemia

Leukemia, Acute Myeloid, Reduced Survival In, Somatic

Acute Myeloid Leukaemia

Leukemia, Myelocytic, Acute

Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome

Secondary Aml

Acute Myelocytic Leukemia

Acute Myeloid Leukemia, Somatic

Leukemia, Acute Myeloid, Somatic

Myeloid Leukemia, Acute, M4/M4eo Subtype, Somatic

Acute Myeloblastic Leukaemia

Acute Myelogenous Leukaemia

Aml - Acute Myeloid Leukemia

Acute Myeloid Leukemia With Cebpa Somatic Mutations

Aml With Cebpa Somatic Mutations

Inherited Acute Myeloid Leukemia

Familial Aml

Inherited Aml

Pure Familial Aml

Pure Familial Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia

Therapy-Related Aml And Myelodysplastic Syndrome

Acute Myeloid Leukemia, Secondary

Acute Non-Lymphoblastic Leukemia

Acute Non-Lymphocytic Leukemia

Acute Biphenotypic Leukemia

Acute Undifferentiated Leukemia

Acute Myeloblastic Leukaemia With Multilineage Dysplasia

Acute Myeloid Leukaemia With Multilineage Dysplasia Without Mention Of Remission

Acute Myeloid Leukaemia With Myelodysplasia-Related Features
疾病名称 别名
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

相关产品

Approval
生物活性分子 (4)
目录号 产品名 作用方式
纯度 是否罕见病
HY-A0003 Lenalidomide Inducer 99.95% 是
HY-14658 Thalidomide Inducer 99.92% 是
HY-A0003B Lenalidomide hemihydrate Inducer 99.67% 是
HY-A0003A Lenalidomide hydrochloride / 否
Clinical Phase
生物活性分子 (8)
目录号 产品名 作用方式
纯度 Phase
HY-101291 Iberdomide Inducer 98.83% Phase 3
HY-115997 PROTAC HSP90 degrader BP3 Inhibitor 98.56% Phase 3
HY-130800 Eragidomide 99.86% Phase 2
HY-146237 Golcadomide Modulator 97.01% Phase 2
HY-158101 BMS-986365 Degrader 99.92% Phase 2
HY-153341 CFT1946 Degrader 99.84% Phase 2
HY-153321 NX-5948 Degrader 99.33% Phase 1
HY-145776 ALV1 96.88% Phase 1
Pre-clinical Phase
生物活性分子 (353)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-101488 CC-885 99.85% 否
HY-114421 FKBP12 PROTAC dTAG-13 Degrader 99.75% 否
HY-134582 dCBP-1 Inhibitor 99.44% 否
HY-12214A NVP-2 99.60% 否
HY-160695 PT-179 99.91% 否
HY-148333 MS177 98.00% 否
HY-132199 SJ6986 Degrader 98.00% 否
HY-123937 THAL-SNS-032 Inhibitor 99.16% 否
HY-130665 TL12-186 Inhibitor 99.63% 否
HY-129603 SI-109 Inhibitor 99.91% 否
HY-141881 PROTAC-O4I2 99.66% 否
HY-123941 FKBP12 PROTAC dTAG-7 Inhibitor 99.07% 否
HY-145765 JQAD1 98.70% 否
HY-137206 ALV2 98.07% 否
HY-41547 Thalidomide 4-fluoride Inducer 99.92% 否
HY-125876 PROTAC Bcl2 degrader-1 Inhibitor 99.80% 否
HY-133120 INY-03-041 Inhibitor 99.74% 否
HY-103596 Thalidomide-4-OH Inducer 99.85% 否
HY-155008 PROTAC HK2 Degrader-1 Degrader 98.66% 否
HY-139344 FC-11 Degrader 99.70% 否
HY-103597 Thalidomide-O-COOH Inducer 99.85% 否
HY-126534A Abemaciclib metabolite M18 hydrochloride Inhibitor 98.01% 否
HY-133137 SJF620 Inhibitor 98.98% 否
HY-131717 Thalidomide-NH-CH2-COOH Inducer 98.20% 否
HY-43722 Lenalidomide-Br 99.86% 否
HY-114420 AP1867-2-(carboxymethoxy) Inhibitor 99.85% 否
HY-128845 PROTAC CRBN Degrader-1 99.84% 否
HY-136262 CRBN-6-5-5-VHL 99.98% 否
HY-23095 Thalidomide-5-OH Inducer 99.65% 否
HY-145696 SJ10542 Inhibitor 99.92% 否
HY-147158 ZXH-1-161 Modulator 98.92% 否
HY-151902 SJ988497 98.05% 否
HY-133557 XZ739 99.06% 否
HY-145282 MS170 Inhibitor 99.72% 否
HY-130988 Ipatasertib-NH2 99.64% 否
HY-133144 Lenalidomide-OH 99.48% 否
HY-14658A (S)-Thalidomide Inducer 99.65% 否
HY-148369 U7D-1 99.65% 否
HY-111594 Homo-PROTAC cereblon degrader 1 99.43% 否
HY-132857A ZXH-4-130 TFA 99.71% 否
HY-W077589 Lenalidomide-5-aminomethyl hydrochloride 98.77% 否
HY-122725B Lenalidomide-C5-NH2 hydrochloride 98.44% 否
HY-144995 BSJ-02-162 Inhibitor 96.87% 否
HY-W072954 Lenalidomide-5-Br 99.00% 否
HY-115881 SR-1114 99.04% 否
HY-153803 GBD-9 Inhibitor 99.76% 否
HY-130737 Pomalidomide 4'-alkylC5-acid 98.78% 否
HY-122653A CCT367766 formic 98.02% 否
HY-139539 Thalidomide-5-COOH Inducer 99.97% 否
HY-158113 CBPD-409 Degrader / 否
HY-130952 Thalidomide-O-C8-COOH Inducer 97.44% 否
HY-130714 TD-165 Inhibitor 99.41% 否
HY-136688 MI-389 99.34% 否
HY-139186 PROTAC KRAS G12C degrader-1 99.55% 否
HY-149843 LC-MB12 99.23% 否
HY-161574 LLC0424 Inhibitor 98.42% 否
HY-131318 Lenalidomide-I 99.90% 否
HY-130296 Palbociclib-propargyl 95.23% 否
HY-130504 Propargyl-PEG1-acid ≥97.0% 否
HY-150616 SJPYT-195 99.41% 否
HY-114406 TD-106 98.67% 否
HY-130683 Lenalidomide-propargyl-C2-NH2 hydrochloride 98.04% 否
HY-141481 DP-C-4 Inhibitor 98.15% 否
HY-138881 Lenalidomide-6-F 99.63% 否
HY-W093272 Thalidomide-5,6-F Inducer 99.84% 否
HY-129608 Lenalidomide-acetylene-C5-COOH 99.26% 否
HY-147099 dTAG-47-NEG 97.8% 否
HY-131159 Thalidomide-O-C8-Boc Inducer 95.12% 否
HY-158239 MS181 Inhibitor 98.36% 否
HY-130991 K-Ras ligand-Linker Conjugate 6 / 否
HY-133120A INY-03-041 trihydrochloride Inhibitor 99.27% 否
HY-122830 DD-03-171 Degrader 98.65% 否
HY-123215 CC-17369 98.13% 否
HY-123324 Pomalidomide-5-OH 99.46% 否
HY-126457 Thalidomide-propargyl Inducer 99.97% 否
HY-126534S Abemaciclib metabolite M18-d8 Inhibitor 98.47% 否
HY-130716 Thalidomide-NH-C10-COOH Inducer 97.50% 否
HY-131232 Desmorpholinyl Navitoclax-NH-Me Inhibitor 98.64% 否
HY-131295 PD0325901-O-C2-dioxolane Inhibitor 98.76% 否
HY-138040 CRBN modulator-1 98.00% 否
HY-147858 PROTAC EGFR degrader 7 99.99% 否
HY-147858A PROTAC EGFR degrader 7 diTFA 99.19% 否
HY-159098 dWIZ-1 Degrader / 否
HY-161536 PROTAC EGFR degrader 9 / 否
HY-162014 WDR5 degrader-1 / 否
HY-162704 JMV7048 Degrader / 否
HY-W249500 2-Methoxyphenyl dihydrouracil / 否
HY-130682 Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride / 否
HY-130707 K-Ras ligand-Linker Conjugate 3 / 否
HY-130823 K-Ras ligand-Linker Conjugate 5 96.96% 否
HY-133137A SJF620 hydrochloride Inhibitor 99.28% 否
HY-44148 FAK ligand-Linker Conjugate 1 98.91% 否
HY-114407 TD-428 Inhibitor / 否
HY-115446A Lenalidomide-C4-NH2 hydrochloride 98.85% 否
HY-126534 Abemaciclib metabolite M18 Inhibitor / 否
HY-131887 Pomalidomide-C6-COOH 98.02% 否
HY-132856 Lenalidomide-C5-amido-Boc 95.10% 否
HY-139336 Pomalidomide-C5-azide 97.46% 否
HY-139548 Thalidomide-5-methyl Inducer 99.87% 否
HY-143286A PF15 TFA Degrader 99.72% 否
HY-155268 Pomalidomide-5-C12-NH2 hydrochloride 98.07% 否
HY-156591 PROTAC MLKL Degrader-1 Degrader 99.76% 否
HY-158045 PROTAC PARP1 degrader-1 Inhibitor / 否
HY-158381 PROTAC PTP1B degrader 1 Degrader / 否
HY-161633 PROTAC EGFR degrader 11 Degrader / 否
HY-161741 VinclozolinM2-2204 Degrader / 否
HY-44063 Thalidomide-NH-PEG3-NH-Boc Inducer 97.20% 否
HY-A0003S Lenalidomide-d5 Inducer 99.32% 否
HY-W076696 Lenalidomide-4-OH 98.57% 否
HY-W129872 Thalidomide-5-CH2-NH2 hydrochloride Inducer 98.55% 否
HY-W342590 CRBN ligand-9 ≥98.0% 否
HY-W457950 Thalidomide-5-propargyl / 否
HY-W584518 Thalidomide-5-O-CH2-COOH 95.02% 否
HY-W998345 SMART1 Inhibitor / 否
HY-130949B Thalidomide-4-O-C7-NH2 hydrochloride 99.80% 否
HY-149561 Thalidomide-5-O-C4-NH2 hydrochloride 99.98% 否
HY-122725A Lenalidomide-C5-NH2 TFA 98.94% 否
HY-129775 K-Ras ligand-Linker Conjugate 1 / 否
HY-129776 K-Ras ligand-Linker Conjugate 2 / 否
HY-130988A Ipatasertib-NH2 dihydrochloride / 否
HY-136160 Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride Inducer / 否
HY-141486 (Rac)-PROTAC PARP/EGFR ligand 1 / 否
HY-145226 XY-06-007 Inhibitor / 否
HY-145281 MS98 Inhibitor / 否
HY-122653 CCT367766 / 否
HY-130822 K-Ras ligand-Linker Conjugate 4 98.76% 否
HY-130981 FN-1501-propionic acid / 否
HY-137465 CG428 Degrader / 否
HY-112811 PROTAC CDK9 degrader-2 Inhibitor / 否
HY-130612 PROTAC BRD2/BRD4 degrader-1 Inhibitor / 否
HY-130713 Thalidomide-C2-amido-C2-COOH Inducer / 否
HY-130963B Thalidomide-4-O-C10-NH2 hydrochloride 95.57% 否
HY-130965B Thalidomide-PEG3-NH2 hydrochloride Inducer 98.02% 否
HY-131717A Thalidomide-NH-CH2-COOH TFA / 否
HY-131875 Pomalidomide 4'-alkylC3-acid / 否
HY-132288 Pom-8PEG 95.09% 否
HY-132857 ZXH-4-130 / 否
HY-132862 ZXH-4-137 Chemical / 否
HY-132944 (R)-Pomalidomide-pyrrolidine Chemical / 否
HY-138882 Lenalidomide-4-aminomethyl / 否
HY-138882A Lenalidomide-4-aminomethyl hydrochloride / 否
HY-139540 Pomalidomide-6-OH 98.09% 否
HY-139541 Pomalidomide-5-O-CH3 / 否
HY-139542 Pomalidomide-6-O-CH3 / 否
HY-139543 Thalidomide-5-PEG2-Cl Inducer / 否
HY-139544 Thalidomide-5-propoxyethanamine Inducer / 否
HY-139545 Thalidomide-4-C3-NH2 hydrochloride Inducer / 否
HY-139546 Thalidomide-5-propargyne-NH2 hydrochloride Inducer / 否
HY-139547 Thalidomide-5,6-Cl Inducer / 否
HY-139549 Thalidomide-benzo Inducer / 否
HY-139996 Pomalidomide-C5-Dovitinib / 否
HY-143286 PF15 Inhibitor / 否
HY-143435 AG6033 Inducer / 否
HY-145925C (S,R)-CFT8634 Inhibitor / 否
HY-14658S Thalidomide-d4 Inducer 98.03% 否
HY-148276 KTX-497 / 否
HY-148277 KTX-612 / 否
HY-148662 Pomalidomide-PEG5-C2-NH2 hydrochloride / 否
HY-149845 PROTAC GSK-3β Degrader-1 Degrader / 否
HY-150799 CRBN ligand-1 / 否
HY-150839 E3 ligase Ligand PG / 否
HY-151886 NU223612 Inhibitor / 否
HY-153166 PT-65 Degrader / 否
HY-153337 Pomalidomide-C11-NH2 / 否
HY-153337A Pomalidomide-C11-NH2 hydrochloride / 否
HY-153959 Thalidomide-O-amido-C11-COOH / 否
HY-155072 PROTAC BTK Degrader-5 Degrader / 否
HY-155258 Pomalidomide-PEG7-NH2 hydrochloride 97.53% 否
HY-155259 Pomalidomide-5-C3-NH2 hydrochloride 96.02% 否
HY-155260 Pomalidomide-5-C4-NH2 hydrochloride / 否
HY-155261 Pomalidomide-5-C5-NH2 hydrochloride / 否
HY-155262 Pomalidomide-5-C6-NH2 hydrochloride / 否
HY-155263 Pomalidomide-5-C7-NH2 hydrochloride / 否
HY-155264 Pomalidomide-5-C8-NH2 hydrochloride / 否
HY-155265 Pomalidomide-5-C9-NH2 hydrochloride 98.68% 否
HY-155266 Pomalidomide-5-C10-NH2 hydrochloride 95.00% 否
HY-155267 Pomalidomide-5-C11-NH2 hydrochloride 98.20% 否
HY-155269 Pomalidomide-5-C13-NH2 hydrochloride / 否
HY-155270 Pomalidomide-5-C14-NH2 hydrochloride / 否
HY-156164 Thalidomide-5-NH-PEG2-NH2 hydrochloride Inducer / 否
HY-156170 Thalidomide-5-NH-PEG5-NH2 hydrochloride / 否
HY-156726 Pomalidomide-amino-PEG4-C4-Cl / 否
HY-157426 GSPT1 degrader-3 Degrader / 否
HY-157510 Thalidomide-O-C3-azide / 否
HY-157511 Thalidomide-O-C5-azide / 否
HY-157515 Thalidomide 4'-ether-PEG2-azide / 否
HY-157587 E3 ligase Ligand-Linker Conjugate 29 / 否
HY-157588 (S)-Thalidomide-Piperazine-CH2-Pyrrolidine-C2-OH Inducer / 否
HY-157594 E3 ligase Ligand-Linker Conjugate 37 / 否
HY-157595 E3 ligase Ligand-Linker Conjugate 38 / 否
HY-157599 E3 ligase Ligand-Linker Conjugate 65 / 否
HY-157600 E3 ligase Ligand-Linker Conjugate 66 / 否
HY-157635 E3 Ligase Ligand-linker Conjugate 92 / 否
HY-157636 E3 Ligase Ligand-linker Conjugate 93 / 否
HY-157637 E3 Ligase Ligand-linker Conjugate 94 / 否
HY-157747 E3 Ligase Ligand-linker Conjugate 99 / 否
HY-157748 E3 Ligase Ligand-linker Conjugate 100 / 否
HY-157756 E3 Ligase Ligand-linker Conjugate 104 / 否
HY-157757 E3 Ligase Ligand-linker Conjugate 105 / 否
HY-157758 (S)-Thalidomide-piperazine-pyrimidine-piperazine-C2-O-CH2-COO-C(CH3)3 Inducer / 否
HY-157759 (S)-Thalidomide-piperazine-pyrimidine-piperazine-C2-O-C2-OH Inducer / 否
HY-157760 (S)-Thalidomide-piperazine-pyrimidine-piperazine-C2-OH Inducer / 否
HY-157761 E3 Ligase Ligand-linker Conjugate 106 / 否
HY-157767 Abd110 Inhibitor / 否
HY-158062 LC-1-40 / 否
HY-158152 PROTAC CRBN ligand-2 / 否
HY-158325 PROTAC FLT-3 degrader 4 / 否
HY-160017 Pomalidomide-5'-C8-acid / 否
HY-160241 Lenalidomide-C5-acid 96.36% 否
HY-160244 Pomalidomide 5'-piperazine-4-methylpiperidine dihydrochloride / 否
HY-161128 Lenalidomide 4'-PEG1-amine dihydrochloride / 否
HY-161129 Lenalidomide 4'-PEG2-amine dihydrochloride / 否
HY-161130 Lenalidomide 4'-PEG3-amine dihydrochloride / 否
HY-161131 Lenalidomide 4'-alkyl-C3-azide / 否
HY-161183 (S)-Thalidomide-O-(1S,3r)-C4H4-N(Me)-Pip-C2-O-C-boc Inducer / 否
HY-161184 Deoxy-thalidomide-piperidine-C-piperazine-C2-OH Inducer / 否
HY-161186 Thalidomide-piperidine-C-azetidine-C2-O-C-boc Inducer / 否
HY-161187 Thalidomide-piperidine-1,6-diazaspiro[3.3]heptane-boc Inducer / 否
HY-161188 Thalidomide-O-C4H4-N(Me)-piperidine-C2-OH Inducer / 否
HY-161189 Thalidomide-2,6-diazaspiro[3.4]octane-C-piperidine-C2-O-C-boc Inducer / 否
HY-161190 Thalidomide-piperidine-C-2,6-diazaspiro[3.3]heptane-C2-OH Inducer / 否
HY-161191 Thalidomide-azetidine-piperazine-C2-O-C2-OH Inducer / 否
HY-161192 Thalidomide-O-C4H4-N(Me)-piperidine-C-boc Inducer / 否
HY-161193 Thalidomide-piperazine-(R)-C-pyrrolidine-C-boc Inducer / 否
HY-161195 Deoxy-thalidomide-piperidine-C-piperazine-C-boc Inducer / 否
HY-161196 Thalidomide-2,6-diazaspiro[3.4]octane-C-piperidine-C-boc Inducer / 否
HY-161197 Thalidomide-2,6-diazaspiro[3.4]octane-C-piperidine-C2-O-C2-OH Inducer / 否
HY-161198 Thalidomide-azetidine-pyrrolidine-C-piperidine-C-boc Inducer / 否
HY-161199 Thalidomide-azetidine-pyrrolidine-C-piperidine-C2-OH Inducer / 否
HY-161200 Thalidomide-piperazine-C-azetidine-C2-OH Inducer / 否
HY-161201 Thalidomide-piperazine-pyrimidine-piperazine-C-boc Inducer / 否
HY-161202 Thalidomide-piperidine-O-piperidine-C2-OH Inducer / 否
HY-161203 Thalidomide-azetidine-piperazine-C2-O-C-boc Inducer / 否
HY-161204 Thalidomide-O-C4H4-N(Me)-piperidine-boc Inducer / 否
HY-161205 Thalidomide-PIP-(R)C-pyrrolidine-boc Inducer / 否
HY-161206 Thalidomide-Pip-C-Pip-O-C-boc Inducer / 否
HY-161208 Deoxy-thalidomide-Pip-C-PIP-boc Inducer / 否
HY-161209 Thalidomide-2,6-diazaspiro[3.4]octane-C-Pip-boc Inducer / 否
HY-161210 Thalidomide-azetidine-C-PIP-C-boc Inducer / 否
HY-161250 Pomalidomide-NH-PEG6-amide-C2-CPI-1612 / 否
HY-161632 PROTAC EGFR degrader 10 Degrader / 否
HY-161654 PROTAC SOS1 degrader-10 Degrader / 否
HY-161668 Ru-Poma / 否
HY-161696 AN5777 Inducer / 否
HY-162180 E3 Ligase Ligand-linker Conjugate 2 / 否
HY-162181 E3 Ligase Ligand-linker Conjugate 5 / 否
HY-162182 E3 Ligase Ligand-linker Conjugate 7 / 否
HY-162183 E3 Ligase Ligand-linker Conjugate 9 / 否
HY-162184 E3 ligase Ligand-Linker Conjugate 11 / 否
HY-162185 E3 Ligase Ligand-linker Conjugate 12 / 否
HY-162186 E3 Ligase Ligand-linker Conjugate 13 / 否
HY-162187 E3 Ligase Ligand-linker Conjugate 14 / 否
HY-162189 E3 Ligase Ligand-linker Conjugate 16 / 否
HY-162190 E3 Ligase Ligand-linker Conjugate 17 / 否
HY-162191 E3 Ligase Ligand-linker Conjugate 18 / 否
HY-162192 E3 Ligase Ligand-linker Conjugate 20 / 否
HY-162194 E3 Ligase Ligand-linker Conjugate 28 / 否
HY-162195 E3 ligase Ligand-Linker Conjugate 34 / 否
HY-162196 E3 ligase Ligand-Linker Conjugate 39 / 否
HY-162197 E3 ligase Ligand-Linker Conjugate 41 / 否
HY-162198 E3 ligase Ligand-Linker Conjugate 43 / 否
HY-162199 E3 Ligase Ligand-linker Conjugate 45 / 否
HY-162200 E3 Ligase Ligand-linker Conjugate 47 / 否
HY-162203 E3 Ligase Ligand-linker Conjugate 51 / 否
HY-162204 E3 Ligase Ligand-linker Conjugate 54 / 否
HY-162205 E3 Ligase Ligand-linker Conjugate 55 / 否
HY-162206 E3 Ligase Ligand-linker Conjugate 58 / 否
HY-162538 LC-MI-3 / 否
HY-162702 AZ'3137 Degrader / 否
HY-163168 aTAG 4531 Inhibitor / 否
HY-163221 (S)-Thalidomide-piperazine-(1S,4r)-cyclohexane-N(Me)-Boc Inducer / 否
HY-163225 (S)-Thalidomide-piperazine-(1S,4r)-cyclohexane-NH-Boc Inducer / 否
HY-163226 (1R,5S)-Thalidomide-3,8-diazabicyclo[3.2.1]octane-(1R,4r)-cyclohexane-NH-Boc Inducer / 否
HY-163227 (1R,4R)-Thalidomide-2,5-diazabicyclo[2.2.1]heptane-(1R,4r)-cyclohexane-NH-Boc Inducer / 否
HY-163229 (1r,4r)-Thalidomide-piperidine-N(Me)-CH-cyclohexane-NH-Boc Inducer / 否
HY-163230 (1R,5S)-Thalidomide-3,8-diazabicyclo[3.2.1]octane-Boc Inducer / 否
HY-163232 Phthalimidinoglutarimide-piperidine-NH-Boc / 否
HY-163233 Phthalimidinoglutarimide-5-piperazine / 否
HY-163234 Phthalimidinoglutarimide-piperidine-NH2 / 否
HY-163236 Thalidomide-piperidine-O-azetidine-acetic acid Inducer / 否
HY-163237 Thalidomide-piperidine-O-azetidineethanol Inducer / 否
HY-163238 Thalidomide-azetidine-CH-piperazineethanol Inducer / 否
HY-163239 (R)-Thalidomide-piperazine-pyrrolidineethanol Inducer / 否
HY-163757 PROTAC PD-L1 degrader-1 Inhibitor / 否
HY-163851 PROTAC Vif degrader-1 Inhibitor / 否
HY-163922 CRBN ligand-1-piperidine-Me / 否
HY-163938 PROTAC erf3a Degrader-1 / 否
HY-168274 PROTAC TRIB2 degrader-1 Inducer / 否
HY-168614 MGD-4 Degrader / 否
HY-168615 MGD-28 Degrader / 否
HY-169077 IKZF3 degrader 1 Degrader / 否
HY-169082 JQ-1 (carboxylic acid)-NH-C2-NH-COOH / 否
HY-169232 PCC16 chloride Degrader / 否
HY-169235 DHHC3 degrader 1 / 否
HY-42771 Thalidomide-4-O-CH2-COO(t-Bu) Inducer / 否
HY-N12876 (18α)-Oleanolic acid / 否
HY-RS03143 CRBN Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-W077589A Lenalidomide-5-aminomethyl / 否
HY-W145436 Thalidomide-Piperazine 5-fluoride hydrochloride Inducer / 否
HY-W584513 Thalidomide-NH-(CH2)2-NH-Boc / 否
HY-W584514 Thalidomide-NH-(CH2)2-NH2 TFA Inducer / 否
HY-W584515 Thalidomide-NH-(CH2)3-NH-Boc / 否
HY-W584516 Thalidomide-5-NH-CH2-COO(t-Bu) / 否
HY-W584517 Thalidomide-5-O-CH2-COO(t-Bu) / 否
HY-W584520 Thalidomide-4-NH-PEG1-NH-Boc / 否
HY-W584521 Thalidomide-4-NH-PEG1-NH2 TFA Inducer / 否
HY-W584522 Thalidomide-4-NH-PEG1-COO(t-Bu) / 否
HY-W584523 Thalidomide-4-NH-PEG1-COOH TFA / 否
HY-W584524 Thalidomide-4-NH-PEG2-COO(t-Bu) / 否
HY-139332 Pomalidomide 4'-PEG6-azide / 否
HY-139333 Pomalidomide 4'-PEG5-azide / 否
HY-139339 Pomalidomide 4'-alkylC6-azide / 否
HY-139341 Pomalidomide 4'-alkylC3-azide / 否
HY-139343 Pomalidomide 4'-alkylC2-azide / 否
HY-149559 Thalidomide-5-O-C2-NH2 hydrochloride 98.01% 否
HY-149560 Thalidomide-5-O-C3-NH2 hydrochloride 99.08% 否
HY-149562 Thalidomide-5-O-C5-NH2 hydrochloride / 否
HY-149563 Thalidomide-5-O-C6-NH2 hydrochloride / 否
HY-149564 Thalidomide-5-O-C7-NH2 hydrochloride 98.13% 否
HY-149565 Thalidomide-5-O-C8-NH2 hydrochloride / 否
HY-149566 Thalidomide-5-O-C9-NH2 hydrochloride 99.59% 否
HY-149567 Thalidomide-5-O-C10-NH2 hydrochloride 99.37% 否
HY-149568 Thalidomide-5-O-C11-NH2 hydrochloride / 否
HY-149569 Thalidomide-5-O-C12-NH2 hydrochloride 99.90% 否
HY-149570 Thalidomide-5-O-C13-NH2 hydrochloride 99.93% 否
HY-149571 Thalidomide-5-O-C14-NH2 hydrochloride 97.70% 否
HY-149572 Thalidomide-4-O-C9-NH2 hydrochloride / 否
HY-149573 Thalidomide-4-O-C11-NH2 hydrochloride 99.94% 否
HY-149574 Thalidomide-4-O-C12-NH2 hydrochloride 95.57% 否
HY-149575 Thalidomide-4-O-C13-NH2 hydrochloride 99.75% 否
HY-149576 Thalidomide-4-O-C14-NH2 hydrochloride 99.85% 否
HY-155255 Thalidomide-5-PEG2-NH2 hydrochloride / 否
HY-155256 Thalidomide-5-PEG6-NH2 hydrochloride / 否
HY-155257 Thalidomide-5-PEG7-NH2 hydrochloride / 否
HY-156159 Thalidomide-NH-C9-NH2 hydrochloride / 否
HY-156160 Thalidomide-NH-C10-NH2 hydrochloride / 否
HY-156161 Thalidomide-NH-C13-NH2 hydrochloride / 否
HY-156162 Thalidomide-NH-C14-NH2 hydrochloride / 否
HY-156163 Thalidomide-5-NH-PEG1-NH2 hydrochloride / 否
HY-156165 Thalidomide-5-NH-PEG3-NH2 hydrochloride / 否
HY-156171 Thalidomide-5-NH-PEG6-NH2 hydrochloride / 否
HY-156172 Thalidomide-NH-PEG6-NH2 hydrochloride / 否
HY-157514 Thalidomide 4'-ether-PEG1-azide / 否
HY-159164 PROTAC CRBN ligand-3 / 否
HY-160531 IKZF1-degrader-1 Degrader / 否
HY-161134 Lenalidomide 4'-PEG2-azide / 否
HY-161538 Lenalidomide-C6-Br / 否
HY-161675 Lenalidomide-5-bromopentanamide / 否
HY-163210 Pomalidomide 5'-fluoro-6'-piperazine-4-methylpiperidine hydrochloride / 否
HY-164391 Pomalidomide-C2-amide-C4-Br / 否
HY-164891 EM12-FS / 否
HY-A0003S2 Lenalidomide-13C5,15N Inducer / 否
HY-W760183 EM12-SO2F / 否

直系同源

种属 基因名 来源 基因 ID
Macaca mulatta CRBN VGNC VGNC:71607
Felis catus CRBN VGNC VGNC:61162
Rattus norvegicus CRBN RGD RGD:1310533
Canis familiaris CRBN VGNC VGNC:108241
Bos taurus CRBN VGNC VGNC:27690
Mus musculus CRBN MGD MGI:1913277
Others CRBN NCBI
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z